National Institute on Drug Abuse (NIDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).
National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.
National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.
Top-decile sponsor footprint
National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
335 total, page 5 of 7
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS
NCT00079560
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
NCT00218127
Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine
NCT00218166
Using Smokeless Tobacco Products With Lower Nicotine Levels to Reduce Negative Effects of Smokeless Tobacco Use
NCT00218244
Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1
NCT00046813
Reserpine for the Treatment of Cocaine Dependence - 1
NCT00033033
A Study of Cabergoline for the Treatment of Cocaine Dependence - 1
NCT00033111
Evaluation of Benztropine for Cocaine Craving - 2
NCT00000333
Ondansetron for the Treatment of Cocaine Dependence - 1
NCT00033085
Randomized Trial of the Positive Action Program in Hawaii Schools
NCT00328445
Serotonin, Impulsivity, and Cocaine Dependence Treatment
NCT00297505
Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts
NCT00142779
Lofexidine for Opiate Withdrawal - 1
NCT00032942
Integrated Treatment for Cocaine and Mood Disorders - 1
NCT00227812
Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
NCT00032929
Substance Dependent Teens - Impact of Treating Depression Study 1 - 1
NCT00061113
Reduction of Smoking in Cardiac Disease Patients
NCT00469885
Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence
NCT01034384
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
NCT00134888
Naltrexone Augmentation of Nicotine Patch Therapy - 1
NCT00218153
Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2
NCT00218010
Examining the Role of Negative Emotional States on Sedative Drug Use in Individuals With Post-Traumatic Stress Disorder
NCT00244335
Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
NCT00249509
Medication Adherence Therapy for Opioid Abusing Pain Patients
NCT00249587
Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings
NCT00217932
Maintenance Treatment for Abstinent Smokers
NCT00063323
Chemical Dependency and Smoking Cessation: Patient's Views - 1
NCT00051883
Student Athlete Testing Using Random Notification
NCT00451854
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
NCT00015340
Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence
NCT01208935
Progesterone Treatment in Female Smokers - 12
NCT00000295
Bupropion as an Adjunct to the Nicotine Patch Plus CBT
NCT00142831
Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9
NCT00015132
Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10
NCT00000293
Motivation and Patch Treatment for HIV-positive Smokers
NCT00551720
Effects of Labetalol on Nicotine Administration in Humans - 14
NCT00000297
Effects of Carvedilol on Cocaine Use in Humans - 11
NCT00000294
Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3
NCT00015054
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
NCT00307203
PET Assays of Striatal Dopamine Marker in Cocaine Craving
NCT01036516
High Dose Nimodipine Treatment Adjunct - 1
NCT00000332
Role of Metabolites in Nicotine Dependence (3) - 6
NCT00000289
Cocaine-Methylphendidate Interaction Study - 4
NCT00015067
Role of Metabolites in Nicotine Dependence (4) - 13
NCT00000296
Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7
NCT00015106
Effects of Labetalol on Human Cocaine Use - 8
NCT00000291
Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1
NCT00000320
Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20
NCT00000238
Dextroamphetamine as an Adjunct in Cocaine Treatment - 1
NCT00000304
Risperidone for Treatment of Cocaine Dependence in Outpatients - 12
NCT00000347
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 121 |
| Phase 3 | 14 |
| Phase 4 | 16 |
What is open in the National Institute on Drug Abuse (NIDA) pipeline
14 recruiting of 335 indexed (4% open); 292 completed (87%).
Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).
Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide
Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 335 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Genentech · 332 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Akebia Therapeutics · 4% recruiting · 24 trials
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this National Institute on Drug Abuse (NIDA) page
335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.
- 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.